People with pulmonary hypertension (PH) who had elevated blood levels of the trimethylamine N-oxide (TMAO) molecule were at a five times greater risk of a poor prognosis than patients who didn’t have high levels, according to a recent study. High levels of this gut-derived metabolite were generally linked to…
News
Two new biomarkers to assess pulmonary arterial hypertension (PAH) were discovered through large-scale analysis of gene activity profiles using computer software, a study reported. These biomarkers, the activity of the genes PNISR and HNRNPH1, may help diagnose PAH, monitor its progression, or measure responses to therapy. They also may highlight…
People with pulmonary arterial hypertension (PAH) may lack some key vitamins and minerals their bodies need daily to stay healthy, which may lessen their vitality, according to a small study from the Netherlands. Besides the known lack of vitamin D and iron, researchers observed lower than recommended levels of…
Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…
Increasing the levels of the Tex261 protein — either as a preventive or therapeutic approach — eased the symptoms of pulmonary arterial hypertension (PAH) in a rat model of the disease, a new study shows. These benefits were seen after the scientists had found that PAH development in…
Dosing is complete in a Phase 1 clinical trial of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib that’s being investigated to treat pulmonary arterial hypertension (PAH). Aerami plans to advance the experimental therapy to a proof-of-concept Phase 2 trial in the first half of 2023. To do so,…
Unhealthy changes in cognition, like a focus on worries, can lead to anxiety in people with pulmonary hypertension(PH), while those in behavior, like social avoidance, may cause depression, according to a U.K. study. Greater dyspnea, or shortness of breath, was also a contributing factor when paired with these cognitive or…
Infants with pulmonary arterial hypertension (PAH) who were put on Adempas (riociguat) after Revatio (sildenafil) and other therapies failed to control their symptoms showed improvements in lung and right heart function, according to data from a small study. They also had a reduction in high blood pressure…
Children with pulmonary arterial hypertension (PAH) experience lower quality of life because of their functional impairments, especially if they have poor right heart function, according to a study conducted in Hungary. Despite PAH treatment, the health-related quality of life (HRQoL) in these children was similar to that of…
Combination therapy — a treatment approach used to target multiple pathways involved in pulmonary arterial hypertension (PAH) — improves hemodynamics (blood flow) in treatment-naïve patients, according to a new pooled analysis of several studies. A measure of the resistance to blood flow, called pulmonary vascular resistance (PVR), decreased significantly…
Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial. Results showed that the therapy improved blood flow in patients’ lungs, but did not affect blood pressure elsewhere in the body. “The promising pulmonary selectivity and…
Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new subcutaneous or under-the-skin infusion pump for treprostinil — a generic form of Remodulin — for treating people with pulmonary arterial hypertension (PAH). The exclusive rights to promote and market treprostinil injection belong…
